Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jemperli
Pharma
AZ, GSK make case for broad I-O uses in endometrial cancer
For AstraZeneca's and GSK's PD-(L)1/PARP regimens, the contribution of a PARP drug in a subset of endometrial cancer patients have come into question.
Angus Liu
Mar 18, 2024 11:05am
GSK tees up AstraZeneca rivalry with Jemperli-Zejula combo data
Dec 18, 2023 11:13am
In industry first, GSK's PD-1 trial hits overall survival goal
Oct 30, 2023 2:00am
ESMO: AZ proposes Lynparza and Imfinzi in endometrial cancer
Oct 22, 2023 3:10am
ESMO: Jemperli appears to show survival edge over Keytruda
Oct 20, 2023 10:00am
GSK's Jemperli loses initial edge on Merck's Keytruda
Mar 27, 2023 5:15pm